Velcade approved for untreated multiple myeloma
The FDA has approved Velcade (bortezomib injection, from Millennium) for patients with previously untreated multiple myeloma. This approval is based on results from the VISTA trial which showed a 30% complete remission rate with Velcade in combination with melphalan and prednisone compared to 4% for the control arm of melphalan and prednisone alone.
Velcade is already indicated for the treatment of multiple myeloma or mantle cell lymphoma in patients who have received at least one prior therapy.
For more information call (866) VELCADE or visit www.velcade.com.